Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

July 18, 2024 Merck Animal Health

As a result of the acquisition, Merck Animal Health now owns innovative products such as CLYNAV®, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease and IMVIXA®, an anti-parasitic sea lice treatment and water treatment products for warm water production, complementing Merck Animal Health’s vaccine portfolio.